Results
93
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
93 companies
Ascentage Pharma Group International
Market Cap: HK$28.8b
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
6855
HK$78.40
7D
5.2%
1Y
93.1%
CARsgen Therapeutics Holdings
Market Cap: HK$10.9b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$19.72
7D
1.9%
1Y
347.2%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$131.2b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$562.50
7D
10.7%
1Y
181.5%
Alnylam Pharmaceuticals
Market Cap: US$60.4b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$460.99
7D
2.5%
1Y
71.0%
Caris Life Sciences
Market Cap: US$8.5b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$29.71
7D
-0.07%
1Y
n/a
RemeGen
Market Cap: HK$70.0b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$122.60
7D
14.6%
1Y
591.1%
Xbrane Biopharma
Market Cap: SEK 682.6m
A biotechnology company, engages in the development, manufacture, and sale of biosimilars.
XBRANE
SEK 0.27
7D
7.9%
1Y
45.3%
Akeso
Market Cap: HK$128.8b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$139.80
7D
3.0%
1Y
107.7%
Mereo BioPharma Group
Market Cap: US$326.1m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$2.05
7D
15.8%
1Y
-53.4%
Cutia Therapeutics
Market Cap: HK$3.2b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$9.05
7D
3.0%
1Y
-41.8%
Legend Biotech
Market Cap: US$6.0b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.29
7D
-1.6%
1Y
-32.4%
Guard Therapeutics International
Market Cap: SEK 401.3m
A pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden.
GUARD
SEK 19.90
7D
-11.6%
1Y
-20.4%
Mesoblast
Market Cap: AU$3.3b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.54
7D
2.0%
1Y
88.1%
Alterity Therapeutics
Market Cap: AU$108.8m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.01
7D
-9.1%
1Y
233.3%
Beijing Luzhu Biotechnology
Market Cap: HK$4.8b
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.
2480
HK$24.38
7D
-1.9%
1Y
3.3%
Xspray Pharma
Market Cap: SEK 2.5b
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden.
XSPRAY
SEK 60.10
7D
0.8%
1Y
26.1%
Madrigal Pharmaceuticals
Market Cap: US$10.0b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$449.64
7D
6.3%
1Y
117.7%
Achieve Life Sciences
Market Cap: US$158.4m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$3.19
7D
7.4%
1Y
-36.6%
Tenaya Therapeutics
Market Cap: US$273.8m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$1.60
7D
7.4%
1Y
-15.8%
Capricor Therapeutics
Market Cap: US$357.5m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$7.97
7D
22.2%
1Y
-53.3%
RenovoRx
Market Cap: US$49.1m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.27
7D
8.5%
1Y
23.3%
Vanda Pharmaceuticals
Market Cap: US$301.4m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$5.16
7D
6.8%
1Y
14.7%
OS Therapies
Market Cap: US$63.3m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.99
7D
-5.7%
1Y
-33.8%
Aldeyra Therapeutics
Market Cap: US$314.6m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.32
7D
7.5%
1Y
1.7%
Dizal (Jiangsu) Pharmaceutical
Market Cap: CN¥33.3b
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases.
688192
CN¥72.43
7D
0.8%
1Y
65.3%
Soleno Therapeutics
Market Cap: US$3.2b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$57.98
7D
-7.6%
1Y
18.4%
ARS Pharmaceuticals
Market Cap: US$997.2m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.28
7D
7.8%
1Y
-26.6%
Immutep
Market Cap: AU$411.0m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.28
7D
9.8%
1Y
-9.7%
AC Immune
Market Cap: US$300.8m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.13
7D
7.6%
1Y
-7.7%
Syndax Pharmaceuticals
Market Cap: US$1.4b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$15.44
7D
2.7%
1Y
-17.4%
Aelis Farma
Market Cap: €15.8m
A clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.
AELIS
€1.17
7D
6.4%
1Y
-71.9%
Arcutis Biotherapeutics
Market Cap: US$2.4b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$21.25
7D
27.0%
1Y
108.8%
Lipigon Pharmaceuticals
Market Cap: SEK 91.5m
Develops drugs for lipid related diseases in Sweden.
LPGO
SEK 0.15
7D
7.1%
1Y
-40.7%
GNI Group
Market Cap: JP¥131.3b
Engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally.
2160
JP¥2,364.00
7D
-3.0%
1Y
-18.9%
Cynata Therapeutics
Market Cap: AU$52.2m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.22
7D
7.3%
1Y
-20.0%
Devyser Diagnostics
Market Cap: SEK 2.3b
Engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia.
DVYSR
SEK 140.00
7D
0.4%
1Y
10.2%